Camena Bioscience has appointed Gregory McGuinness as CEO as it looks to scale its antibody discovery platform. The biotechnology company, which sees itself as a pioneer in enzymatic DNA synthesis for AI-driven antibody discovery, has appointed McGuinness to support the company’s growth, including its commercialisation of AI-driven antibody… Read More
Dr Kerstin Papenfuss, Deep Science Ventures, and Ben Holland, Antiverse, discuss how generative AI is helping advance antibody discovery. The therapeutic antibody, once 'the next big thing,' has matured into a cornerstone of modern medicine, standing alongside small molecules as a staple of drug development. Yet, while artificial intelligence (AI) has dramatically… Read More
A new Infographic is now available to download from Thermo Fisher Scientific, entitled ‘Optimize Your mAb Manufacturing with Proven Analytical Strategies‘. Key takeaways: Boost Workflow Efficiency: Discover how end-to-end testing can enhance the efficiency of your monoclonal antibody production process. Ensure Compliance: Learn about the importance of accurate and… Read More
Key takeaways: Boost Workflow Efficiency: Discover how end-to-end testing can enhance the efficiency of your monoclonal antibody production process. Ensure Compliance: Learn about the importance of accurate and precise testing at various production stages to meet or exceed regulatory guidelines. Guarantee Quality: Understand how proper testing ensures product safety, quality, and potency throughout… Read More
A new case study is now free to download entitled ‘How Pierre Fabre Laboratories enhances their antibody developability platform with NanoTemper’s Prometheus Panta.’ In this case study, learn how Dr Elsa Wagner from Pierre Fabre Laboratories put together a comprehensive developability platform for monoclonal… Read More
In this case study, learn how Dr Elsa Wagner from Pierre Fabre Laboratories put together a comprehensive developability platform for monoclonal antibodies (mAbs), using combined thermal and colloidal stability parameters from the Prometheus Panta instrument. You’ll learn about: How Pierre Fabre Laboratories approaches developability assessment… Read More
Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More
Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More
Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More
Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More
Watch this engaging and informative webinar on Fujifilm Wako’s groundbreaking advancements in rabbit monoclonal antibody discovery. Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with its proprietary single B-cell cloning technique, paving the way… Read More
Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More
Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More
Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More
Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More
Download this new Application Note to discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants. Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach… Read More
